Last reviewed · How we verify
Xenical, Pegasys, Copegus
This is a combination antiviral therapy for hepatitis C that uses a nucleoside analog and an interferon to inhibit viral replication.
This is a combination antiviral therapy for hepatitis C that uses a nucleoside analog and an interferon to inhibit viral replication. Used for Chronic hepatitis C infection (genotype 1-6), Obesity/weight management (orlistat component).
At a glance
| Generic name | Xenical, Pegasys, Copegus |
|---|---|
| Also known as | Xenical (orlistat), Pegasys (PEG-Interferon alpha-2a) |
| Sponsor | Brooke Army Medical Center |
| Drug class | Antiviral combination therapy (interferon + nucleoside analog); Lipase inhibitor |
| Target | Hepatitis C virus NS5B polymerase; pancreatic lipase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology; Obesity |
| Phase | FDA-approved |
Mechanism of action
Xenical (orlistat) is a lipase inhibitor for weight management, while Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) together form a standard hepatitis C treatment regimen. Pegasys is a long-acting interferon that activates innate immunity against HCV, and Copegus is a nucleoside analog that inhibits viral RNA polymerase, working synergistically to suppress hepatitis C virus replication.
Approved indications
- Chronic hepatitis C infection (genotype 1-6)
- Obesity/weight management (orlistat component)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hemolytic anemia
- Thrombocytopenia
- Depression/psychiatric effects
- Gastrointestinal disturbance (orlistat)
- Headache
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xenical, Pegasys, Copegus CI brief — competitive landscape report
- Xenical, Pegasys, Copegus updates RSS · CI watch RSS
- Brooke Army Medical Center portfolio CI